Outcomes of HIV-positive patients lost to follow-up in African treatment programmes

Tropical Medicine and International Health

Volumn 22, Issue 4, 2017, Pages 375-387

  Zürcher, Kathrin ^a   Mooser, Anne ^a   Anderegg, Nanina ^a   Tymejczyk, Olga ^b   Couvillon, Margaret J ^a   Nash, Denis ^b   Egger, Matthias ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

antiretroviral therapy; HIV; loss to follow up; mortality; sub Saharan Africa

Indexed keywords

ANTIMICROBIAL ACTIVITY; CONFIDENCE INTERVAL; DISEASE TREATMENT; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; PROBABILITY; PUBLIC HEALTH;

AFRICA SOUTH OF THE SAHARA; CD4 LYMPHOCYTE COUNT; FOLLOW UP; HOME VISIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MORTALITY; PROGRAM EVALUATION; REVIEW; RURAL AREA; SYSTEMATIC REVIEW; TREATMENT INTERRUPTION; TREATMENT OUTCOME; URBAN AREA; ADULT; CHILD; HEALTH CARE DELIVERY; HIV INFECTIONS; META ANALYSIS;

SUB-SAHARAN AFRICA;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CHILD; DELIVERY OF HEALTH CARE; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP;

EID: 85013382493     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12843     Document Type: Review

References (61)

1. UNAIDS. Global AIDS Update 2016. Geneva, 2016. (Available from: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf) [31 May 2016].
2. UNAIDS. ‘15 by 15’ – a global target achieved, 2015. (Available from: http://www.unaids.org/en/resources/documents/2015/15_by_15_a_global_target_achieved) [1 May 2016].
3. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90. An ambitious treatment target to help end the AIDS epidemic, 2014. (Available from: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf) [5 April 2015].
4. Egger M, Spycher BD, Sidle J et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med 2011: 8: e1000390.
5. Geng EH, Odeny TA, Lyamuya RE et al. Estimation of Mortality among HIV-infected people on antiretroviral therapy treatment in east Africa: a sampling based approach in an observational, multisite, cohort study. Lancet HIV 2015: 2: e107–e116.
6. Yiannoutsos CT, Johnson LF, Boulle A et al. Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sex Transm Infect 2012: 88(Suppl 2): i33–i43.
7. Boulle A, Van Cutsem G, Hilderbrand K et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010: 24: 563–572.
8. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE 2009: 4: e5790.
9. Wilkinson LS, Skordis-Worrall J, Ajose O et al. Self-transfer and mortality amongst adults lost to follow-up in ART programmes in low- and middle-income countries: systematic review and meta-analysis. Trop Med Int Heal 2015: 20: 365–379.
10. Cornell M, Lessells R, Fox MP et al. Mortality among adults transferred and lost to follow-up from antiretroviral therapy programmes in South Africa: a multicenter cohort study. J Acquir Immune Defic Syndr 2014: 67: e67–e75.
11. Geng EH, Odeny TA, Lyamuya R et al. Retention in care and patient-reported reasons for undocumented transfer or stopping care among HIV-infected patients on antiretroviral therapy in Eastern Africa: application of a sampling-based approach. Clin Infect Dis 2016: 62: 935–944.
12. Egger M, Ekouevi DK, Williams C et al. Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2012: 41: 1256–1264.
13. McMahon JH, Elliott JH, Hong SY, Bertagnolio S, Jordan MR. Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. PLoS ONE 2013: 8: e56047.
14. Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 2010: 29: 3046–3067.
15. Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008: 61: 41–51.
16. Johnson LF, Dorrington RE, Laubscher R et al. A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. J Int AIDS Soc 2015: 18: 20628.
17. Grimwood A, Fatti G, Mothibi E, Malahlela M, Shea J, Eley B. Community adherence support improves programme retention in children on antiretroviral treatment: a multicentre cohort study in South Africa. J Int AIDS Soc 2012: 15: 17381.
18. Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Heal 2010: 15: 405–413.
19. Kiragga AN, Castelnuovo B, Musomba R et al. Comparison of methods for correction of mortality estimates for loss to follow-up after ART initiation: a case of the Infectious Diseases Institute, Uganda. PLoS ONE 2013: 8: e83524.
20. Onoka CA, Uzochukwu BS, Onwujekwe OE et al. Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. Pathog Glob Heal 2012: 106: 46–54.
21. Van Cutsem G, Ford N, Hildebrand K et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS ONE 2011: 6: e14684.
22. Mutevedzi PC, Lessells RJ, Newell ML. Disengagement from care in a decentralised primary health care antiretroviral treatment programme: cohort study in rural South Africa. Trop Med Int Heal 2013: 18: 934–941.
23. Ardura-Garcia C, Feldacker C, Tweya H et al. Implementation and operational research: early tracing of children lost to follow-up from antiretroviral treatment: true outcomes and future risks. J Acquir Immune Defic Syndr 2015: 70: e160–e167.
24. Dalal RP, MacPhail C, Mqhayi M et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008: 47: 101–107.
25. Krebs DW, Chi BH, Mulenga Y et al. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. AIDS Care 2008: 20: 311–317.
26. Makunde WH, Francis F, Mmbando BP et al. Lost to follow up and clinical outcomes of HIV adult patients on antiretroviral therapy in care and treatment centres in Tanga city, North-Eastern Tanzania, Tanzan. J Health Res 2012: 14: 250–6.
27. McGuire M, Munyenyembe T, Szumilin E et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health 2010: 15(Suppl 1): 55–62.
28. Peltzer K, Ramlagan S, Khan MS, Gaede B. The social and clinical characteristics of patients on antiretroviral therapy who are ‘lost to follow-up’ in KwaZulu-Natal, South Africa: a prospective study. SAHARA J 2011: 8: 179–186.
29. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA 2008: 300: 506–507.
30. Henriques J, Pujades-Rodriguez M, McGuire M et al. Comparison of methods to correct survival estimates and survival regression analysis on a large HIV African cohort. PLoS ONE 2012: 7: e31706.
31. Bisson GP, Gaolathe T, Gross R et al. Overestimates of survival after HAART: Implications for global scale-up efforts. PLoS ONE 2008: 3: 1–6.
32. Yu JK-L, Chen SC-C, Wang K-Y et al. True outcomes for patients on antiretroviral therapy who are “lost to follow-up” in Malawi. Bull World Health Organ 2007: 85: 550–554.
33. Budgell EP, Maskew M, Long L, Sanne I, Fox MP. Does most mortality in patients on ART occur in care or after lost to follow-up? Evidence from the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr 2015: 70: 323–328.
34. Mben JM, Kouanfack C, Essomba CN et al. Operational research and HIV policy and guidelines: lessons from a study of patients lost to follow-up from a public antiretroviral treatment program in Cameroon. J Public Heal Policy 2012: 33: 462–477.
35. Weigel R, Hochgesang M, Brinkhof MW et al. Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis 2011: 11: 31.
36. Caluwaerts C, Maendaenda R, Maldonado F, Biot M, Ford N, Chu K. Risk factors and true outcomes for lost to follow-up individuals in an antiretroviral treatment programme in Tete, Mozambique. Int Health 2009: 1: 97–101.
37. Rachlis B, Ochieng D, Geng E et al. Implementation and operational research: evaluating outcomes of patients lost to follow-up in a large comprehensive care treatment program in western Kenya. J Acquir Immune Defic Syndr 2015: 68: e46–e55.
38. Maskew M, MacPhail P, Menezes C, Rubel D. Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 2007: 97: 853–857.
39. Mekuria LA, Prins JM, Yalew AW, Sprangers MAG, Nieuwkerk PT. Retention in HIV care and predictors of attrition from care among HIV-infected adults receiving combination anti-retroviral therapy in Addis Ababa. PLoS ONE 2015: 10: e0130649.
40. Tweya H, Feldacker C, Estill J et al. Are they really lost? ‘True’ status and reasons for treatment discontinuation among HIV infected patients on antiretroviral therapy considered lost to follow up in Urban Malawi. PLoS ONE 2013: 8: e75761.
41. Saka B, Landoh DE, Patassi A et al. Loss of HIV-infected patients on potent antiretroviral therapy programs in Togo: risk factors and the fate of these patients. Pan Afr Med J 2013: 15: 35.
42. Wubshet M, Berhane Y, Worku A, Kebede Y. Death and seeking alternative therapy largely accounted for lost to follow-up of patients on ART in northwest Ethiopia: a community tracking survey. PLoS ONE 2013: 8: e59197.
43. Alamo S, Wabwire-Mangen F, Kenneth E, Sunday P, Laga M, Colebunders RL. Task-shifting to community health workers: evaluation of the performance of a peer-led model in an antiretroviral program in Uganda. AIDS Patient Care STDS 2012: 26: 101–107.
44. Talisuna-Alamo S, Colebunders R, Ouma J et al. Socioeconomic support reduces nonretention in a comprehensive, community-based antiretroviral therapy program in Uganda. J Acquir Immune Defic Syndr 2012: 59: e52–e59.
45. Egger M, Schneider M. Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998: 316: 140–144.
46. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Heal 2010: 15(Suppl 1): 48–54.
47. Rosen S, Ketlhapile M. Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Heal. 2010: 15(Suppl 1): 98–104.
48. O'Connor C, Osih R, Jaffer A. Loss to follow-up of stable antiretroviral therapy patients in a decentralized down-referral model of care in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2011: 58: 429–432.
49. IeDea, Collaborations ARTC, Avila D et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014: 65: e8–e16.
50. Koller M, Patel K, Chi BH et al. Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2015: 68: 62–72.
51. Mutimura E, Addison D, Anastos K et al. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda. AIDS 2015: 29: 67–76.
52. Nash D, Wu Y, Elul B, Hoos D, El Sadr W. International Center for AIDS Care and Treatment Programs. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS 2011: 25: 1523–1533.
53. Hoffman S, Wu Y, Lahuerta M et al. Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS 2014: 28: 2429–2438.
54. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998: 316: 61–66.
55. Siegfried N, Busgeeth K, Certain E. Scope and geographical distribution of African medical journals active in 2005. S Afr Med J 2006: 96: 533–8.
56. Fox M, Bor J, MacLeod W et al. Is retention on ART underestimated due to patient transfers? Estimating system-wide retention using a national labs database in South Africa. In: 21st International AIDS Conference. Durban, South Africa: TUAB0205. (Available from: http://www.aids2016.org/Portals/0/File/AIDS2016_Abstracts_LOW.pdf?ver=2016-08-10-154247-087).
57. Fox MP, Rosen S. Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008-2013. J Acquir Immune Defic Syndr 2015: 69: 98–108.
58. Mills EJ, Bakanda C, Birungi J et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011: 155: 209–216.
59. Nsanzimana S, Remera E, Kanters S et al. Life expectancy among HIV-positive patients in Rwanda: A retrospective observational cohort study. Lancet Glob Heal 2015: 3: e169–e177.
60. Kessler J, Nucifora K, Li L, Uhler L, Braithwaite S. Impact and cost-effectiveness of hypothetical strategies to enhance retention in care within HIV treatment programs in East Africa. Value Health 2015: 18: 946–955.
61. Alamo ST, Colebunders R, Ouma J et al. Return to normal life after AIDS as a reason for lost to follow-up in a community-based antiretroviral treatment program. J Acquir Immune Defic Syndr 2012: 60: e36–e45.